A composite microbial preparation and its application
Through the use of complex microbial preparations, including the combination of Lactobacillus plantarum and the addition of lyophilized protective agents, the problem of major side effects of existing microbial preparations in the treatment of hypertension is solved, and the effective inhibition of angiotensin in the ordinary environment is achieved. Convert enzyme activity and maintain healthy blood pressure.
Patent Information
- Application Number
- CN202310856237.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-07-13
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2043-07-13
AI Technical Summary
Existing microbial preparations have great side effects in the treatment of hypertension, and the product quality is limited, making it difficult to effectively play a role in ordinary environments.
Using phytonum 2-33, phytonum 43, and phytonum 10 are compounded at 1-3:1:1 mass ratio, combined with lyophilized protective agent to prepare a compound microbial lyophilized powder preparation, and fermented milk During the preparation process, a complex microbial preparation is added to inhibit the activity of angiotensin-converting enzymes and maintain the health of blood pressure.
It provides high-quality composite microbial preparations with good storage and tolerance, can exert probiotic effects in the body, inhibit angiotensin-converting enzyme activity, and provide safer methods for improving hypertension.
Smart Images

Figure CN116875502B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of microbial preparations, and in particular relates to a composite microbial preparation and its application. Background Art
[0002] Microbial preparations are also called probiotic preparations or live bacteria preparations. Microbial preparations can effectively stimulate the development of animal intestines and have the function of regulating the body's immune function; at the same time, as a type of beneficial flora, microecological preparations can rapidly proliferate in the intestines and maintain the balance of intestinal flora, playing their role in inhibiting intestinal inflammation and promoting the absorption of important nutrients. The quality of microbial preparations includes the number of surviving flora in the microbial preparations and the length of time they can be stored. Therefore, when preparing microbial preparations, in order to obtain high-quality products, it is necessary to screen the protective agent to ensure its protective function for probiotics. The current level of research on microbial preparations in China is still relatively backward, and the quality of the products it produces is also relatively limited.
[0003] Fermented dairy products refer to an acidic, coagulated dairy product formed by the fermentation of specific bacteria. Fermented milk not only contains all the nutrients in fresh milk, but is also rich in a variety of active probiotics and corresponding organic acids and other nutrients. With the gradual improvement of economic income levels and the popularization of relevant nutrition and health knowledge, the general public's demand for dairy products and their diversification and functionalization has become increasingly obvious. Studies have found that the metabolites produced by certain specific lactic acid bacteria used in fermented milk have an inhibitory effect on angiotensin-converting enzyme, thereby regulating blood pressure.
[0004] Usually, most of the treatments for hypertension are to use drugs to regulate blood pressure, but this will produce many side effects. Therefore, the development of composite microecological preparations with good storage properties, which can function better in ordinary environments and improve hypertension, provides more choices and safer improvement methods for patients with hypertension. Summary of the invention
[0005] In view of this, the object of the present invention is to provide a high-quality composite microbial preparation that can inhibit the activity of angiotensin converting enzyme and maintain a healthy level of blood pressure.
[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0007] A composite microbial preparation comprises: Lactobacillus plantarum 2-33, Lactobacillus plantarum 43 and Lactobacillus plantarum 10 mixed in a mass ratio of 1-3:1:1.
[0008] Preferably, the Lactobacillus plantarum 2-33, Lactobacillus plantarum 43 and Lactobacillus plantarum 10 are compounded in a mass ratio of 1:1:1.
[0009] Another object of the present invention is to provide a product containing the composite microbial preparation, wherein the product is prepared as a composite microbial freeze-dried powder preparation by adding a freeze-drying protectant.
[0010] Preferably, the lyoprotectant comprises the following components in percentage by mass: 10.0-14.0% skim milk, 5.0-7.0% sodium glutamate and 2.4-3.0% Tween-80.
[0011] Another object of the present invention is to provide a fermented milk for maintaining a healthy blood pressure level, which is fermented using the composite microbial preparation.
[0012] Preferably, the fermented milk is prepared by the following steps: fresh milk and white sugar are mixed and sterilized, the composite microbial preparation is added to the sterilized liquid, the mixture is mixed evenly, and the mixture is cultured in a constant temperature incubator at 37-42°C.
[0013] Preferably, the solid-liquid ratio of the white sugar to the fresh milk is 6-8:100 g / mL.
[0014] Preferably, the solid-liquid ratio of the composite microbial preparation to the sterilized liquid is 5-8:100 g / mL.
[0015] Another object of the present invention is to provide the use of the composite microbial preparation, the product containing the composite microbial preparation and the fermented milk in the preparation of products for maintaining healthy blood pressure levels.
[0016] Preferably, the product for maintaining healthy blood pressure level can inhibit the activity of angiotensin converting enzyme.
[0017] Compared with the prior art, the present invention has the following beneficial effects:
[0018] The present invention provides a composite microbial preparation, which has a high number of live probiotics, has strong tolerance in strong acid environments and bile salt environments, can pass through the gastrointestinal tract smoothly and has a high number of live bacteria, can play a probiotic role in the body, and has good storage properties. The fermented milk prepared using the composite microbial preparation of the present invention has an appropriate acidity range, an appropriate viscosity range, a smooth texture, and a stable texture and structure. The fermented milk supernatant has a good inhibitory effect on angiotensin converting enzyme (ACE). It provides more choices and safer improvement methods for patients with hypertension. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 : Results of the test on the tolerance of compound microecological preparations to pH 2.0;
[0020] Figure 2 : Results of the bile salt tolerance test of compound microecological preparations;
[0021] Figure 3 : Experiment on compound microecological preparations simulating artificial gastric juice;
[0022] Figure 4 :Hippuric acid standard curve;
[0023] Figure 5 :HPLC spectrum of hippuric acid standard;
[0024] Figure 6 : HPLC spectrum of fermented milk supernatant. DETAILED DESCRIPTION
[0025] The invention provides a composite microbial preparation, which comprises: Lactobacillus plantarum 2-33, Lactobacillus plantarum 43 and Lactobacillus plantarum 10 compounded in a mass ratio of 1-3:1:1, preferably in a mass ratio of 1:1:1.
[0026] The present invention compounds Lactobacillus plantarum 2-33, Lactobacillus plantarum 43 and Lactobacillus plantarum 10, which can play a probiotic role in the body, inhibit the activity of angiotensin converting enzyme, and maintain a healthy blood pressure level.
[0027] In the present invention, the plant lactobacillus 2-33 is a strain disclosed in the document "Screening and identification of potential probiotic lactic acid bacteria and their biological characteristics" (He Yuxing et al. Modern Food Science and Technology, 2021, 37(11): 50-57+67.); the plant lactobacillus 43 is a strain disclosed in the document "Screening and identification of γ-aminobutyric acid-producing lactic acid bacteria and ultraviolet mutagenesis research" (Tian Rui et al. Food Industry Science and Technology, 2018, 39(17): 128-132.); the plant lactobacillus 10 is a strain disclosed in the document "Research on the fermentation characteristics of γ-aminobutyric acid-producing plant lactobacillus and its application in functional yogurt" (Gao Luyao. Inner Mongolia Agricultural University, 2017.).
[0028] The Lactobacillus plantarum 2-33, Lactobacillus plantarum 43 and Lactobacillus plantarum 10 described in the present invention are all provided by the Food Quality and Safety Teaching and Research Section of Inner Mongolia Agricultural University.
[0029] The strains of the present invention are activated before compounding, and the strain cryopreservation tubes of Lactobacillus plantarum 2-33, Lactobacillus plantarum 43 and Lactobacillus plantarum 10 are placed in a water bath to melt, and as an practicable manner, the water bath temperature is 37° C.; the melted bacterial liquid is added into an MRS liquid culture medium, and preferably the volume ratio of the bacterial liquid to the culture medium is 2:100; the culture medium is placed at 36-38° C. for expansion culture, and preferably the culture medium is expanded to 100 mL; and after the culture is completed, it is placed at 4° C. for standby use.
[0030] As an practicable manner, the present invention centrifuges the three activated strains, discards the supernatant, collects the bacterial sludge, and mixes the bacterial sludge according to proportion.
[0031] Wherein, the centrifugal speed is 4000-8000 r / min, preferably the centrifugal speed is 5500-6500 r / min; the centrifugation is 10-15 min, preferably the centrifugation is 12-14 min.
[0032] The MRS liquid culture medium is: 10.0 g of peptone, 5.0 g of yeast powder, 20.0 g of glucose, 5.0 g of anhydrous sodium acetate, 10.0 g of beef extract, 2.0 g of diammonium citrate, 2.0 g of dimethyl phosphate, 1.0 mL of Tween-80, 0.58 g of magnesium sulfate, 0.25 g of manganese sulfate, 1.0 L of distilled water, and the pH is adjusted to 6.2-6.4. Sterilize at 121°C for 15 min.
[0033] The present invention provides a product containing the composite microorganism preparation, wherein the product is prepared into a composite microorganism freeze-dried powder preparation by adding a freeze-drying protective agent.
[0034] In the present invention, the lyophilization protective agent comprises the following components in percentage by mass: 10.0-14.0% skim milk, 5.0-7.0% sodium glutamate and 2.4-3.0% Tween-80, preferably 11.7% skim milk, 5.60% sodium glutamate and 2.66% Tween-80.
[0035] The lyophilization protectant added in the present invention has a good protective effect on the composite microecological preparation during the freeze-drying process, and the obtained composite microbial freeze-dried powder preparation has a high survival rate of probiotics and can be stored under normal temperature and low temperature (-20°C, -40°C, -80°C). It can be used after activation.
[0036] As an practicable manner, after the activation culture of Lactobacillus plantarum 2-33, Lactobacillus plantarum 43 and Lactobacillus plantarum 10 of the present invention is completed, the supernatant is discarded by centrifugation to obtain bacterial mud, the bacterial mud is evenly mixed according to a proportion, the bacterial mud is mixed with a freeze-drying protective agent, the mixture is quickly frozen with liquid nitrogen and then freeze-dried using a freeze dryer.
[0037] Wherein, the centrifugal speed is 4000-8000 r / min, preferably the centrifugal speed is 5500-6500 r / min; the centrifugation is 10-15 min, preferably the centrifugation is 12-14 min.
[0038] As an practicable manner, the mixture is quickly frozen with liquid nitrogen and then super-frozen at -80°C, and the mixture is frozen for 6-12 hours; and the mixture is freeze-dried with a freeze dryer for 24-36 hours.
[0039] In the present invention, the bacterial mud and the freeze-drying protective agent are mixed at a mass ratio of 1:3-1:4, preferably at a mass ratio of 1:3.
[0040] The invention provides a fermented milk for maintaining a healthy blood pressure level, which is fermented by using the composite microbial preparation.
[0041] In the present invention, the fermented milk is prepared by the following steps: fresh milk and white sugar are mixed and sterilized, the composite microbial preparation is added to the sterilized liquid, mixed evenly, and cultured in a constant temperature incubator at 37-42°C.
[0042] As an practicable manner, the present invention mixes fresh milk and white sugar, sterilizes the mixture in a 95° C. water bath for 10-12 minutes, and cools the mixture to 37-42° C. for later use.
[0043] In the present invention, the fresh milk and the white sugar can be mixed and then sterilized at 121° C. for 15-20 seconds under high temperature and high pressure.
[0044] As an practicable manner, the sterilized liquid in the present invention is mixed with the composite microbial preparation for 60-180 seconds.
[0045] In the present invention, the material-liquid ratio of the white sugar to the fresh milk is 6-8:100 g / mL.
[0046] In the present invention, the solid-liquid ratio of the composite microbial preparation to the sterilized liquid is 5-8:100 g / mL, preferably 6-7:100 g / mL.
[0047] The fermented milk prepared by the composite microbial preparation of the present invention can inhibit the activity of angiotensin converting enzyme and maintain a healthy blood pressure level.
[0048] The present invention provides the composite microbial preparation, the product containing the composite microbial preparation and the use of the fermented milk in preparing a product for maintaining a healthy blood pressure level; the product for maintaining a healthy blood pressure level can inhibit the activity of angiotensin converting enzyme.
[0049] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.
[0050] Example 1
[0051] A composite microbial preparation: Lactobacillus plantarum 2-33, Lactobacillus plantarum 43 and Lactobacillus plantarum 10 are compounded in a mass ratio of 1:1:1.
[0052] The frozen tubes of Lactobacillus plantarum 2-33, Lactobacillus plantarum 43 and Lactobacillus plantarum 10 were placed in a 37°C water bath to thaw, 20 μL of the thawed bacterial solution was added to 10 mL of MRS liquid culture medium, the culture medium was cultured at 37°C for 16 h, then expanded to 100 mL, and placed at 4°C for use after the culture was completed.
[0053] The three activated strains were centrifuged at 6000 r / min for 10 min respectively, the supernatant was discarded and the bacterial sludge was collected and mixed according to the proportion.
[0054] Example 2
[0055] The difference between this embodiment and embodiment 1 is that Lactobacillus plantarum 2-33, Lactobacillus plantarum 43, and Lactobacillus plantarum 10 are compounded in a mass ratio of 2:1:1.
[0056] Example 3
[0057] The difference between this embodiment and embodiment 1 is that Lactobacillus plantarum 2-33, Lactobacillus plantarum 43, and Lactobacillus plantarum 10 are compounded in a mass ratio of 3:1:1.
[0058] Example 4
[0059] A composite microbial freeze-dried powder preparation
[0060] The protective agents of the freeze-dried powder are: 11.7% skim milk, 5.60% sodium glutamate and 2.66% Tween-80.
[0061] After the three strains were activated in Example 1, the collected bacterial sludge by centrifugation was mixed in proportion. The mixed bacterial sludge was mixed with a freeze-drying protective agent at a mass ratio of 1:3, the mixture was quickly frozen with liquid nitrogen and then frozen at -80°C for 8 hours, and then freeze-dried in a freeze dryer for 30 hours to obtain a composite microbial freeze-dried powder.
[0062] Example 5
[0063] A composite microbial freeze-dried powder preparation
[0064] The protective agent of freeze-dried powder is: 12% skim milk, 6% sodium glutamate and 3% Tween-80.
[0065] After the three strains were activated in Example 2, the collected bacterial sludges were mixed in proportion. The mixed bacterial sludge was mixed with a freeze-drying protective agent at a mass ratio of 1:3, the mixture was quickly frozen with liquid nitrogen and then frozen at -80°C for 10 hours, and then freeze-dried in a freeze dryer for 32 hours to obtain a composite microbial freeze-dried powder.
[0066] Example 6
[0067] A fermented milk for maintaining healthy blood pressure level
[0068] 100 mL of milk was mixed evenly with 8 g of white sugar, sterilized in a 95° C. water bath for 10 min, cooled to 37° C. after sterilization, 5 g of the composite microbial freeze-dried powder preparation prepared in Example 4 was added, mixed for 60 s, and cultured in a 37° C. constant temperature incubator.
[0069] Example 7
[0070] A fermented milk for maintaining healthy blood pressure level
[0071] 100 mL of milk was mixed evenly with 6 g of white sugar, sterilized in a 95° C. water bath for 12 min, cooled to 37° C. after sterilization, added with 7 g of the composite microbial freeze-dried powder preparation prepared in Example 4, mixed for 120 s, and cultured in a constant temperature incubator at 40° C.
[0072] Comparative Example 1
[0073] The difference between this comparative example and Example 4 is that the freeze-dried powder protective agent is: 4.0% glucose, 1.6% glycerol, and 4.0% trehalose.
[0074] Comparative Example 2
[0075] The difference between this comparative example and Example 4 is that the freeze-dried powder protective agent is: 15.0% skim milk, 6.0% sodium glutamate and 2.0% Tween-80.
[0076] Example 8
[0077] This example verifies the tolerance of the composite microbial preparation
[0078] 1. Oral acute toxicity test of compound microecological preparations
[0079] The Kunming mice that had adapted to the environment were randomly divided into two groups, 5 mice per group, namely the female group of composite microecological preparation and the male group of composite microecological preparation. The composite microecological preparation of Example 1 was adjusted to a concentration of 1×10 8 CFU / mL was gavaged, and the control group was gavaged with sterile PBS buffer. Each mouse was gavaged once a day, with a dose of 20mL / kg, and the feed was fed on time every day, and the bedding was changed. The weight changes were recorded on days 1, 3, 5, and 7 after gavage. During the feeding process, the mental state, excretion, respiration, and sudden death of the mice were observed. All mice were killed one week after administration, and the organs were dissected to observe abnormal conditions. The results are shown in Table 1.
[0080] Table 1 Results of oral acute toxicity test of composite probiotic preparations in mice
[0081]
[0082] As can be seen from Table 1, the weight of mice showed a stable upward trend after continuous gavage for 7 days, and no mice died within 7 days, without any symptoms of poisoning; no obvious abnormalities were found in the anatomical results, and the results of the oral acute toxicity test were safe and non-toxic.
[0083] 2. Test on the tolerance of compound microecological preparations to pH 2.0
[0084] In the MRS liquid culture medium, hydrochloric acid was used to adjust the solution pH to 2.0, and the composite microecological preparation of Example 1 was added to the MRS liquid culture medium with a pH of 2.0, and cultured in a constant temperature incubator at 37°C. Samples were taken at 0h, 3h, 6h, 9h and 12h, and the number of viable bacteria was calculated by plate count method. Three parallel tests were performed, and the survival rate was used as a measurement index to evaluate the tolerance of the composite microecological preparation to a low acid environment. The results are as follows: Figure 1 shown.
[0085] The first condition for probiotics to work is to enter the gastrointestinal tract in the form of live bacteria. The probiotics contained in the food must be able to resist gastric acid to reach the intestines and work. Usually, the pH value of gastric juice is maintained at 2.0-3.0, and the food residence time is about 2 hours. The survival rate of the composite microbial preparation of the present invention gradually decreases over time in an environment with a pH of 2.0, but the survival rate of the composite microecological preparation is above 90% at 3 hours; the survival rate at 6 hours is also above 85%. It can be seen that the composite microecological preparation of the present invention has a good tolerance in a strong acidic environment.
[0086] 3. Test on the tolerance of compound microecological preparations to bile salts
[0087] 0.3% bile salt was added to the MRS liquid culture medium, and the composite microecological preparation of Example 1 was added to the MRS culture medium, and cultured in a constant temperature incubator at 37°C. Samples were taken at 0h, 3h, 6h, 9h and 12h, and the number of viable bacteria was calculated by plate count method. Three parallel tests were performed, and the survival rate was used as a measurement index to evaluate the tolerance of the composite microecological preparation to the bile salt environment. The results are as follows: Figure 2 shown.
[0088] After food is digested and absorbed in the stomach, it enters the small intestine, but the bile salts in the small intestine affect the permeability of the cell membrane and thus reduce the survival rate of microorganisms. The bile salt content in the human small intestine is in the range of 0.03%-0.30%. The survival rate of microorganisms in the composite microecological preparation of the present invention is in 0.30% bile salt. As time goes by, the survival rate gradually decreases. However, when staying in bile salt for 3 hours, the survival rate is about 90%; even after staying for 12 hours, the survival rate can still reach more than 70%, which can reach the number of live bacteria that play a probiotic role. It can be seen that the composite microecological preparation of the present invention can survive in a high bile salt environment.
[0089] 4. Tolerance test of composite microecological preparations simulating artificial gastric juice
[0090] Preparation of artificial gastric juice: Take 20mL of 1.0mol / LHCL, adjust the pH to 2.0 with distilled water and 1.0mol / L NaOH solution, then add pepsin at 1.0g / 100mL to completely dissolve it, filter the solution with a 0.22μm sterile filter membrane to obtain artificial gastric juice, which can be used immediately after preparation.
[0091] Take 1 mL of the bacterial solution of the composite microbial preparation in Example 1, inoculate it in 5 mL of artificial simulated gastric fluid with pH 2.0, culture it at 37°C, take samples at 0h, 1h, 2h, 3h and 4h, dilute the bacterial solution using the gradient dilution method, and culture it on MRS solid culture medium. Then, the colony counting method described in GB4789.35-2016 standard was used to calculate the colony forming unit (CFU / g). In order to ensure the accuracy of the results, three parallel tests were performed. The artificial gastric fluid tolerance of the strains was determined by the above method, and the survival rate was calculated by formula (1). The results are as follows: Figure 3 shown.
[0092] Survival rate (%) = N1 / N0; wherein: N0 represents the number of viable bacteria at 0 h; N1 represents the number of viable bacteria after exposure to artificial simulated gastric fluid for 1-4 h.
[0093] The digestive tract is the human body's line of defense against external invaders. The stomach is an important digestive organ of the human body, in which the strong acid environment of pepsin and gastric juice blocks most microorganisms from entering the intestine. The survival rate of microorganisms in the composite microecological preparation of the present invention is in simulated artificial gastric juice. As time goes by, the survival rate gradually decreases. However, when staying in gastric juice for 2 hours, the survival rate is more than 85%; even when staying for 4 hours, the survival rate is still around 80%, which can reach the number of viable bacteria that play a probiotic role. It can be seen that the composite microecological preparation of the present invention can survive in a simulated artificial gastric juice environment.
[0094] Example 9
[0095] This example compares the effects of different lyophilization protectants
[0096] The survival rates of the microorganisms in the composite microbial preparations of Examples 4-5 and Comparative Examples 1-2 before and after freeze-drying were tested, and the results are shown in Table 2.
[0097] Table 2 Number of viable bacteria before and after freeze-drying of composite microbial preparations
[0098]
[0099]
[0100] After freeze-drying, the number of viable probiotic bacteria can reach 5.32×10 9CFU / g, and the survival rate reaches 88.70%. After the freeze-drying protectant is used in the present invention, the composite microecological preparation can be stored at room temperature and low temperature (-20°C, -40°C, -80°C), which effectively increases the number of live bacteria in the composite microbial freeze-dried preparation, can be stored for a long time, and improves the quality of the composite microbial preparation.
[0101] Example 10
[0102] This example compares the inhibitory effect of composite microbial preparations on ACE in fermented milk.
[0103] 1. Borate buffer: Dissolve 19.07g borax in ultrapure water and dilute to 1.0L. Dissolve 12.37g boric acid in ultrapure water and dilute to 1.0L. Take 325mL boric acid solution and 175mL borax solution, mix the two solutions together, adjust the pH of the mixture to 8.3 with sodium hydroxide and hydrochloric acid, then add 17.532g sodium chloride and dilute to 1.0L with a volumetric flask.
[0104] HHL solution: HHL was dissolved in borate buffer to prepare a solution with a concentration of 5.0 mmol / L.
[0105] ACE solution: Add 0.5 mL of borate buffer to 0.1 U ACE and mix well to obtain an ACE solution with a concentration of 200 mU / mL. Divide it into 5 tubes, 0.1 mL per tube. When using, add 0.7 mL of borate buffer to each tube, that is, dilute each tube 8 times to obtain an ACE solution with a concentration of 25 mU / mL.
[0106] 2. Drawing of hippuric acid standard curve
[0107] The hippuric acid standard was dissolved and diluted to 0.2, 0.4, 0.6, 0.8 and 1.0 μg / mL, the sample volume was 10 μL, and the standard curve was drawn with the peak area as the ordinate and the hippuric acid concentration as the abscissa.
[0108] 3. Determination of ACE inhibition rate
[0109] In a 2mL centrifuge tube, take 40μL of the fermented milk supernatant in Example 6, add 40μL ACE solution (25mU / mL), incubate at 37°C for 5min, then add 50L HHL solution for reaction, add 200μL 0.1mol / mL HCl after 60min of reaction to terminate the reaction, use borate buffer as a blank control group, and filter with a 0.45μm filter membrane after the reaction. Mobile phase: 25% acetonitrile (containing 0.1% trifluoroacetic acid), 75% ultrapure water (containing 0.1% trifluoroacetic acid); flow rate: 1.0mL / min; detection wavelength: 228nm; column temperature: 30°C; injection volume: 10μL.
[0110] 4. Data Analysis
[0111] All experiments were repeated three times, and the data results were expressed as "mean ± standard deviation". Design Expert 8.0.5 was used for response surface analysis, and Origin 8.6 was used for graphing. The results are shown in Figure 4-6 shown.
[0112] 5. Results
[0113] Depend on Figure 4 It can be seen that the peak area value of the hippuric acid standard solution increases with the increase of its concentration. The linear regression equation is y=32901x+45.5, and the correlation coefficient R 2 The concentration of hippuric acid standard is in the range of 0-1.0μg / mL, and its concentration has a good linear relationship with the absorbance value. The peak time of hippuric acid is 2.317min, so it can be determined Figure 5 The peak at 2.670min is the hippuric acid content.
[0114] Depend on Figure 6 It can be seen that peak I is the hippuric acid content in the sample, and the peak time is 2.769min. The peak area of the blank group is 227.8, and the peak area of the sample group is 65.30. The peak area of the sample group is significantly reduced, indicating that the sample has a good inhibitory effect on the activity of angiotensin converting enzyme. Substituting into the standard curve formula for calculation, the sample inhibition rate is 66.50%. The fermented milk supernatant prepared by the composite microecological preparation of the present invention has good inhibitory properties against ACE.
[0115] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. Use of a composite microbial preparation in the preparation of a product for assisting in lowering blood pressure, characterized in that: The composite microbial preparation is prepared by mixing Lactobacillus plantarum 2-33, Lactobacillus plantarum 43 and Lactobacillus plantarum 10 in a mass ratio of 1:1:
1.
2. Use of a product containing the composite microbial preparation according to claim 1 in the preparation of a product for assisting in lowering blood pressure, characterized in that: The product containing the composite microbial preparation according to claim 1 is a composite microbial freeze-dried powder preparation prepared by adding a freeze-drying protective agent.
3. The use according to claim 2, characterized in that: The freeze-drying protective agent includes the following components in percentage by weight: 10.0-14.0% skim milk, 5.0-7.0% sodium glutamate and 2.4-3.0% Tween-80.
4. An application of fermented milk in preparing a product for assisting in lowering blood pressure, characterized in that: The fermented milk is fermented using the composite microbial preparation as claimed in claim 1.
5. The use according to claim 4, characterized in that: The fermented milk is prepared by the following steps: fresh milk and white sugar are mixed and sterilized, the composite microbial preparation is added to the sterilized liquid, mixed evenly, and cultured in a constant temperature incubator at 37-42°C.
6. The use according to claim 5, characterized in that: The material-liquid ratio of the white sugar to the fresh milk is 6-8g:100mL.
7. The use according to claim 5, characterized in that: The solid-liquid ratio of the composite microbial preparation to the sterilized liquid is 5-8 g:100 mL.
8. The use according to any one of claims 1 to 7, characterized in that: The auxiliary blood pressure lowering product can inhibit the activity of angiotensin converting enzyme.
